Table of Contents
NEW YORK — Journavx the first and only oral, nonopioid, highly selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute pain in adults, is now available and stocked in retail pharmacies across the U.S. following its FDA approval in late January. It is manufactured by the Boston-based Vertex Pharmaceuticals.
FDA approves Journavx for moderate to severe acute pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Bill Schiffner
Additional information on Journavx:
- Journavx is approved for moderate-to-severe acute pain from any cause – like broken bones, sports injuries, post-surgery, etc.
- Approximately 80M adults in America each year are prescribed a medicine for acute pain. Half of those people (~40M) are prescribed opioids, which while effective, have significant safety and tolerability concerns and addictive potential.
- Journavx fills a critical gap between over-the-counter pain medicines (e.g., aspirin and ibuprofen), which offer only modest relief, and opioids, which are effective but come with serious side effects.
- Journavx also blocks pain signals found in the periphery, not in the brain, providing effective relief of pain without the limitations of currently available therapies, including the addiction potential of opioids.
